Recent Updates
Recently added Catalysts
PYPD Positive Sentiment Score: 70/100

PolyPid to Present at the Barclays Global Healthcare Conference

Tuesday, March 7, 2023 1 min read
Key Takeaway: PolyPid Ltd. is scheduled to present at the Barclays Global Healthcare Conference in Miami from March 14-16, 2023. The company, which focuses on improving surgical outcomes, is currently advancing its lead product candidate D-PLEX100 into Phase 3 clinical trials aimed at preventing surgical site infections. Additionally, PolyPid is exploring the efficacy of another product, OncoPLEX, for treating solid tumors, including glioblastoma. This presentation offers an opportunity for investors to engage with the company during the conference.

Market Sentiment Analysis

POSITIVE FACTORS

  • PolyPid is presenting at a significant healthcare conference, highlighting its visibility in the market.
  • The company is advancing its lead product candidate D-PLEX100 into Phase 3 clinical trials, indicating progress in drug development.
  • PolyPid's proprietary technology has the potential to improve surgical outcomes and manage drug delivery.

Full Press Release Details

PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023.
Barclays Global Investor Conference:
Presentation Date: Tuesday, March 14, 2023
Presentation Time: 4:35 PM Eastern Time
Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.
Tel: +1-908-376-6758
britchie@lifesciadvisors.com

Frequently Asked Questions

What is PolyPid Ltd. focused on?

PolyPid Ltd. is focused on improving surgical outcomes through innovative treatments.

When will PolyPid present at the Barclays Conference?

PolyPid will present on March 14, 2023, at 4:35 PM Eastern Time.

What is D-PLEX100 being tested for?

D-PLEX100 is in Phase 3 trials for preventing abdominal surgical site infections.

What technology does PolyPid use?

PolyPid uses PLEX technology for controlled, prolonged drug release at optimal rates.

What is OncoPLEX targeting?

OncoPLEX is in preclinical stages for treating solid tumors, starting with glioblastoma.

Tags: PYPD Viatris Investor Conferences Healthcare PolyPid surgical outcomes D-PLEX100 healthcare conference
Last updated: Mar 7, 2023